CSI Market
Sign In | Register

Pelthos Therapeutics Inc (PTHS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTHS quarterly Cash Flow →
The data below summarizes Pelthos Therapeutics Inc's cash flow activity from to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023)
Operating Activities
Income-43.32
Depreciation & amortization0.73
Amortization of Other Assets1.82
Accretion Expense2.40
Impairment of Intangible Assets, Finite-lived0.29
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories2.83
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation5.46
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Issuance Cost From Shares Issued On Extension Of Bridge Loan-
Shares Issued For License-
Due From Chromocell Corporation-
Finance Lease Right Of Use Asset Amortization-
Gain Loss On Litigation Settlement-
Gain Loss On Sale Of Accounts Receivable-
Operating Lease Right Of Use Asset Amortization Expense0.07
Increase Decrease In Operating Lease Liability-0.28
Change In Fair Value Of Convertible Debt14.98
Gain Loss Related To Litigation Settlement-
Increase Decrease In Operating Lease Right Of Use Assets0.35
Debt Conversion Converted Instrument Amount0.74
Transfer Of Liabilities To Counterparty For Common Stock-
Account Payable And Accrued Expenses Converted To Notes-
Shares Issued For Payment Of Accrued Interest-
Shares Issued For Payment Of Principal On Loan Payable-
Increase Decrease In Contract With Customer Liability-0.59
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-8.81
Increase (Decrease) in Accounts Payable1.36
Increase (Decrease) in Accrued Liabilities6.16
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-8.27
Other Working Capital0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.46
Discontinued operations0.00
Net Cash flow from Operating Activities-22.59
Investing Activities
Capital Expenditures-0.10
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired2.76
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-7.90
Discontinued operations0.00
Net Cash Flow from Investing Activities-5.24
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings17.75
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.21
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.56
Net Contribution From Chromocell Corporation-
Advance From Chromocell Corporation-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Repurchase Of Common Stock Under Stock Repurchase Plan-
Shares Issued For Cash Under Equity Line Of Credit-
Restricted Cash And Cash Equivalent-
Total Cash Cash Equivalents And Restricted Cash Shown In Statement Of Cash Flows-
Proceeds From P I P E Net27.38
Payments For Recission Of Common Stock-
Proceeds From Shares Issued For Cash Under Equity Line Of Credit-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.51
Restricted Cash Current0.05
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities45.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-22.69
Total Cash Flow17.51
4 historic quarters locked

Sign in to unlock the full Pelthos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Pelthos Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001919246-26-000013

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License